



NOVODIAX

Advancing immunoassays through innovation

Press Release

Novodix receives two awards for Innovative in-vitro Diagnostic Tests for Cancer

Hayward, CA, February 7, 2018– Novodix was voted the “Best Immunoassays Development Company for 2018” and the “Most Innovative IHC Technology company” for the Company’s innovative ihcDirect Products. The award was given at the Third-Annual Biotechnology Awards by GHP (Global Health & Pharma). Novodix is dedicated to advancing tissue-based diagnostics and immunoassays to detect cancer. Novodix’s proprietary, supersensitive enzymatic signal amplification detection system provides a revolutionary 10 minute intraoperative IHC result and accelerates Companion Diagnostic development.

About Novodix:

Novodix, Inc. is a privately held company founded in 2009 and dedicated to advancing tissue-based and cell-based diagnostics and immunoassays. The company developed the innovative ihcDirect platform allowing rapid determination of tissue during intraoperative procedures, and is exploring applications for companion diagnostics. For further information visit our website at www.novodix.com.

For inquiries please contact:

Novodix, Inc.

paul.kortschak@novodix.com

3517 Breakwater Ave

Hayward, CA 94545, USA

Toll Free: +1 (888) 439-2716

Phone: +1 (510) 342-3043